

Day 1: Wednesday, May 25, 2022; Gene Editing**Session Chairs: Harry Dolstra, PhD, Bruce Blazar, MD, and Leslie Kean, MD, PhD**

Time	Topic
8:00 – 9:00AM MT	Genome editing for immune deficiencies – efficacy and safety Paula Cannon, PhD; University of Southern California, California, US
9:00 – 10:00AM MT	Genome Editing of the Blood: Precise and Potent Cell Based Therapies Matthew Poretus, MD, PhD; Stanford Medicine, California, US
10:00 – 10:30AM MT	Break
10:30 – 11:30AM MT	Development and Application of Targeted Epigenetic Editing Angelo Lombardo, PhD; IRCCS Ospedale San Raffaele, Milano, IT
11:30 – 12:30PM MT	Expanding the Horizons of Genome Interventions with CRISPR Tools Anna Cereseto, PhD; University of Trento, Trento, IT
12:30 – 4:30PM MT	Afternoon break – lunch will be available beginning at 12:30PM.
4:30 – 5:30PM MT	Best Abstracts Oral Presentations <ul style="list-style-type: none"> • Beatrice Cianciotti, PhD; Generation of human memory Stem T cells specific for tumor antigens and resistant to inhibitory signals by genome editing • Kayleigh Ingersoll Omdahl, PhD Candidate; Acute GVHD in liver and lungs is mediated by phenotypically analogous but transcriptionally unique T cells • Sawa Ito, MD, PhD; High throughput cloning reveals diverse properties of anti-HA-1 T cell receptors • Marc Eric Kohler, MD, PhD; A novel Adjunctive LAT-Activating CAR T (ALA-CART) platform demonstrates enhanced antigen sensitivity and in vivo efficacy against antigen-low leukemia • Dan Peltier, MD, PhD; Coding and Noncoding Elements of Regulatory Long Noncoding RNA of T Cells (ReLoT) Augment Allogeneic T Cell Function and T Cell Receptor Signal Transduction
5:30 – 6:30PM MT	Poster Hall + Networking Hour
6:30 – 7:30PM MT (Dinner Session)	Extending the Applicability of Immune Effector Therapies Helen Heslop, MD, DSc; Baylor College of Medicine, Texas, US

Day 1 concludes**Day 2: Thursday, May 26, 2022; Graft-versus-Leukemia****Session Chairs: Chiara Bonini, MD and Warren Shlomchik, MD**

Time	Topic
8:00 – 9:00AM MT	Biological Mechanisms and Personalized Therapy of Post-Transplantation Leukemia Relapses Luca Vago, MD, PhD, San Raffaele Scientific Institute, Milan, IT
9:00 – 10:00AM MT	Mechanisms of GVL Resistance Warren Shlomchik, MD; University of Pittsburgh, Pennsylvania, US
10:00 – 10:30AM MT	Break
10:30 – 11:30AM MT	Immune Escape Mechanisms Causing AML Relapse After Allo-HCT Robert Zeiser, MD; University of Freiburg, Breisgau, DE
11:30 – 12:30PM MT	Treating AML with Engineered T cells: Identifying Obstacles to Efficacy and Designing Solutions Philip Greenberg, MD; Fred Hutchinson Cancer Research Center, Washington, US
12:30 – 4:30PM MT	Afternoon break – lunch will be available beginning at 12:30PM.
4:30 – 5:30PM MT	Meet-the-Professor Session
5:30 – 6:30PM MT	Poster Hall + Networking Hour
6:30 – 7:30PM MT (Dinner Session)	Transcriptional Networks in Tumour-Infiltrating T Cells Anjana Rao, PhD; La Jolla Institute for Immunology, California, US

Day 2 concludes**Day 3: Friday, May 27, 2022; Graft-versus-Host disease****Session Chairs: Pavan Reddy, MD and Nicolaus Kröger, MD**

Time	Topic
8:00 – 9:00AM MT	Tissue is the Issue: Insights Into GI Tract Immune Destruction From Single Cell Analysis of Inflammatory Bowel Disease Leslie Kean, MD, PhD; Boston Children's Hospital, Massachusetts, US
9:00 – 10:00AM MT	Next Challenges in GVHD: From Bedside back to the Bench Gerard Socié, MD, PhD; Hôpital Saint-Louis, Paris, FR
10:00 – 10:30AM MT	Break
10:30 – 11:30AM MT	The Microbiome and Graft vs Host Disease Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center, New York, US

11:30 – 1:00PM MT

Best Abstracts Oral Presentations

- Laura McLaughlin, MD; JAK Inhibitors Facilitate Hematopoietic Cell Engraftment Following Allogeneic BMT
- Katherine Oravec-Wilson; Characterization of target organ intrinsic pathways that regulate their sensitivity to pathogenic T cells
- Jonathan Peled, MD, PhD; Nutrition as a predictor of microbiome injury in allo-HCT
- Kevin Quann, MD, PhD; TCF-1+ T Cells Sustain Alloimmune Responses in Graft-vs-Host Disease
- Keisuke Seike, PhD; Mitochondrial complex II controls naive T cell functions
- Symeon Theodoridis, PhD Candidate; Distinct metabolic profiles for effector and regulatory subsets of human alloreactive CD4 T cells
- Victor Tkachev, PhD; Uncovering a novel evolutionary-conserved mechanism to control GI GVHD: Notch pathway blockade leads to beta1/beta7 integrin competition and resulting failure of GI tract infiltration by effector T cells.

1:00 – 1:15PM MT

Closing remarks; conference wrap up

Day 3 concludes

**Sessions speakers are subject to change.*